Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Glioblastoma 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 23Capecitabine 17Cisplatin 11Oxaliplatin 10Fluorouracil 9Leucovorin 8Irinotecan 7Erlotinib Hydrochloride 6pembrolizumab 5Radiotherapy 5Sorafenib 4Interleukin-12 Subunit p35 3Cholangiopancreatography, Endoscopic Retrograde 3Carboplatin 3regorafenib 2dehydroftorafur 2Watchful Waiting 2Trastuzumab 2Pancreaticoduodenectomy 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Long-Term Synaptic Depression 2Lapatinib 2Filgrastim 2Epirubicin 2Drug Therapy 2Dihematoporphyrin Ether 2Chemotherapy, Adjuvant 2Bevacizumab 2trifluridine tipiracil drug combination 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bile Duct Neoplasms × olutasidenib × Clear all
NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡